Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 15/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650752 | 0.91 | UTS2R (0.45) | UTS2RARDRD4 | |
| SCHEMBL15480696 | 0.88 | UTS2R (0.55) | UTS2RDRD4 | |
| SCHEMBL4402669 | 0.87 | UTS2R (0.58) | UTS2R | |
| SCHEMBL4408263 | 0.87 | UTS2R (0.56) | UTS2RDRD4 | |
| SCHEMBL4403510 | 0.85 | AR (0.45) | UTS2RARDRD4ACHEHRH1 | |
| SCHEMBL4408257 | 0.84 | DRD4 (0.51) | UTS2RDRD4 | |
| SCHEMBL4403508 | 0.84 | UTS2R (0.54) | UTS2RDRD4 | |
| SCHEMBL3663526 | 0.81 | AR (0.40) | UTS2RARDRD4HRH1CCR3 | |
| SCHEMBL4403516 | 0.80 | UTS2R (0.54) | UTS2R | |
| SCHEMBL4403534 | 0.79 | UTS2R (0.54) | UTS2RDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | MIDCAP FINANCIAL TRUST | 2014-10-30 | — | — | US | disclosed |
| US-8796254-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8569340-B2 | AMPK-activating piperidinyloxypyiridine carboxamide and sulfonamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8119809-B2 | AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | UTS2R 1156/4885AR 3066/4885DRD4 3588/4885 |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | UTS2R 1156/4885AR 3066/4885DRD4 3588/4885 |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | UTS2R 1535/4885AR 379/4885DRD4 4704/4885 |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | CPT2, SHMT2, CS | UTS2R 1064/4885AR 1278/4885DRD4 3528/4885 |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | UTS2R 514/4885AR 543/4885DRD4 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.